GeneDx Holdings Corp. (WGS)
| Market Cap | 3.86B |
| Revenue (ttm) | 402.19M |
| Net Income (ttm) | 2.08M |
| Shares Out | 28.90M |
| EPS (ttm) | 0.07 |
| PE Ratio | 1,817.00 |
| Forward PE | 149.41 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 257,337 |
| Open | 136.42 |
| Previous Close | 138.70 |
| Day's Range | 130.00 - 138.11 |
| 52-Week Range | 55.17 - 146.00 |
| Beta | 2.06 |
| Analysts | Strong Buy |
| Price Target | 130.63 (-2.24%) |
| Earnings Date | Oct 28, 2025 |
About WGS
GeneDx Holdings Corp., a genomics company, provides genetic testing services. It primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. The company also develops an AI-based platform for NGS analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing. The company is headquartered in Stamford, Connecticut. [Read more]
Financial Performance
In 2024, GeneDx Holdings's revenue was $305.45 million, an increase of 50.79% compared to the previous year's $202.57 million. Losses were -$52.29 million, -70.25% less than in 2023.
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for WGS stock is "Strong Buy." The 12-month stock price target is $130.63, which is a decrease of -2.24% from the latest price.
News
GeneDx to Showcase Advancements in Gene-Disease Discovery, Long-Read Sequencing and More at National Society of Genetic Counselors (NSGC) 2025 Annual Meeting
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx announced it will unveil research findings during four key sessions at the 2025 National Society of Genetic Counselors (NSGC) Annual Meeting.
GeneDx to Participate in Upcoming Investor Conferences
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that company management will participate in upcoming...
GeneDx Holdings Corp. (WGS) Q3 2025 Earnings Call Transcript
GeneDx Holdings Corp. (NASDAQ:WGS) Q3 2025 Earnings Call October 28, 2025 8:30 AM EDT Company Participants Sabrina Dunbar Katherine Stueland - President, CEO & Director Kevin Feeley - Chief Financial...
GeneDx Reports Third Quarter 2025 Financial Results and Business Highlights
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx Holdings Corp. (Nasdaq: WGS) today reported its financial results for the third quarter of 2025.
GeneDx: A Moment Of Reckoning As Market Awaits Q3 Testing Growth
GeneDx Holdings Corp. is poised for strong Q3 results, driven by expanding exome and genome testing in pediatric and neonatal settings. Key metrics for WGS include test volume growth and reimbursement...
GeneDx Holdings Corp. (NASDAQ: WGS) Investor Reminder: Schubert Jonckheer Investigating Possible False Claims
SAN FRANCISCO , Oct. 27, 2025 /PRNewswire/ -- Schubert Jonckheer & Kolbe LLP reminds GeneDx Holdings Corp. (NASDAQ: WGS) investors that the firm is investigating potential legal claims relating to whe...
Halper Sadeh LLC Encourages GeneDx Holdings Corp. Shareholders to Contact the Firm to Discuss Their Rights
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of GeneDx Holdings Corp. (NASDAQ: WGS) breached their fiduciary duties...
GeneDx Showcases Leadership in Genomic Newborn Screening at ICoNS 2025
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx Showcases Leadership in gNBS at ICoNS 2025 with data from more than 22,000 newborns.
GeneDx Granted FDA Breakthrough Device Designation for its ExomeDx™ and GenomeDx™ Testing
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx announces that the FDA has granted Breakthrough Device Designation for its whole genome and exome tests.
GeneDX CEO Katherine Stueland on how the company is using AI to save lives
GeneDX CEO Katherine Stueland discusses how the company is using AI to help deliver "life-changing information." Want to hear the full interview?
GeneDX CEO Katherine Stueland on if the cuts at NIH impact the company
GeneDX CEO Katherine Stueland talks about the impact of federal funding cuts to research programs. Want to hear the full interview?
Illumina constellation mapped read technology uncovers hard-to-see genomic insights in GeneDx pilot
Illumina's up-and-coming constellation innovation delivers accuracy, speed, and ease of use in trial by GeneDx Constellation outperformed orthogonal methods in identifying select difficult-to-map vari...
GeneDx's Blueprint For The Next Healthcare Revolution
GeneDx Holdings is transforming into a global genetic software leader, leveraging its vast database and recent Fabric Genomics acquisition. WGS achieved strong Q2 results: 49% revenue growth, 71% gros...
How GeneDX CEO Katherine Stueland is using AI to save lives
She started her career helping launch breakthrough treatments for HIV and cancer. Today, Katherine Stueland is leading GeneDx — a genetic testing company using genomic insights to diagnose rare diseas...
GeneDx Appoints Dr. Mimi Lee as Chief Precision Medicine Officer
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx today announced Dr. Mimi Lee, MD, PhD, as Chief Precision Medicine Officer.
GeneDx to Partner with Florida's Sunshine Genetics Network, Launching Nation's First State-Backed Genomic Newborn Screening Program
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx today announced its involvement in the Sunshine Genetics Act, establishing the nation's first state-backed genomic newborn screening program.
GeneDx to Launch Autism Partnership Program to Expand Access to Exome and Genome Testing, including Dedicated SHANK3 Program
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx today announced the Autism Partnership Program to expand access to exome and genome testing in partnership with Jaguar Gene Therapy.
GeneDx to Showcase Pioneering Research Findings at American Society of Human Genetics (ASHG) Annual Meeting
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx today announced pioneering scientific contributions that will be presented at the American Society of Human Genetics (ASHG) Annual Meeting.
GeneDx to Report Third Quarter 2025 Financial Results on Tuesday, October 28, 2025
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx today announced it will release financial results for the third quarter of 2025 before the market opens on Tuesday, October 28, 2025.
GeneDx Announces First U.S. National Genomic Newborn Screening Initiative Launched with $14.4 Million NIH Award
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx today announced the launch of BEACONS, the nation's first multi-state genomic newborn screening initiative.
GeneDx Appoints Lisa Gurry as Chief Business Officer to Unlock Data and Information Growth
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS) today announced the appointment of Lisa Gurry as Chief Business Officer, effective immediately.
GeneDx Infinity™ Pioneers a New Era of Genetic Medicine with its Introduction at the American Academy of Pediatrics National Conference
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced it will introduce pediatricians to GeneDx's Infinity...
GeneDx Appoints Visionary AI and Precision Medicine Leader Dr. Thomas Fuchs to Board of Directors
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx Appoints Visionary AI and Precision Medicine Leader Dr. Thomas Fuchs to Board of Directors.
GeneDx Holdings Corp. (WGS) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
GeneDx Holdings Corp. (NASDAQ:WGS) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 8:30 AM EDT Company Participants Katherine Stueland - President, CEO & Director Kevin Feel...
Seer Appoints Isaac Ro to its Board of Directors
REDWOOD CITY, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced it has appointed Isaac Ro to ...